Jennifer Wilder
Science Applications International Corporation
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jennifer Wilder.
Blood | 2013
James N. Kochenderfer; Mark E. Dudley; Robert O. Carpenter; Sadik H. Kassim; Jeremy J. Rose; William G. Telford; Frances T. Hakim; David Halverson; Daniel H. Fowler; Nancy M. Hardy; Anthony R Mato; Dennis D. Hickstein; Juan Gea-Banacloche; Steven Z. Pavletic; Claude Sportes; Irina Maric; Steven A. Feldman; Brenna Hansen; Jennifer Wilder; Bazetta Blacklock-Schuver; Bipulendu Jena; Michael R. Bishop; Ronald E. Gress; Steven A. Rosenberg
New treatments are needed for B-cell malignancies persisting after allogeneic hematopoietic stem cell transplantation (alloHSCT). We conducted a clinical trial of allogeneic T cells genetically modified to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19. T cells for genetic modification were obtained from each patients alloHSCT donor. All patients had malignancy that persisted after alloHSCT and standard donor lymphocyte infusions (DLIs). Patients did not receive chemotherapy prior to the CAR T-cell infusions and were not lymphocyte depleted at the time of the infusions. The 10 treated patients received a single infusion of allogeneic anti-CD19-CAR T cells. Three patients had regressions of their malignancies. One patient with chronic lymphocytic leukemia (CLL) obtained an ongoing complete remission after treatment with allogeneic anti-CD19-CAR T cells, another CLL patient had tumor lysis syndrome as his leukemia dramatically regressed, and a patient with mantle cell lymphoma obtained an ongoing partial remission. None of the 10 patients developed graft-versus-host disease (GVHD). Toxicities included transient hypotension and fever. We detected cells containing the anti-CD19-CAR gene in the blood of 8 of 10 patients. These results show for the first time that donor-derived allogeneic anti-CD19-CAR T cells can cause regression of B-cell malignancies resistant to standard DLIs without causing GVHD.
Journal of Clinical Oncology | 2016
Jennifer N. Brudno; Robert Somerville; Victoria Shi; Jeremy J. Rose; David Halverson; Daniel H. Fowler; Juan Gea-Banacloche; Steven Z. Pavletic; Dennis D. Hickstein; Tangying L. Lu; Steven A. Feldman; Alexander T. Iwamoto; Roger Kurlander; Irina Maric; Andre Goy; Brenna Hansen; Jennifer Wilder; Bazetta Blacklock-Schuver; Frances T. Hakim; Steven A. Rosenberg; Ronald E. Gress; James N. Kochenderfer
PURPOSE Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the transplant donor. DLIs frequently are not effective at eradicating malignancy and often cause graft-versus-host disease, a potentially lethal immune response against normal recipient tissues. METHODS We conducted a clinical trial of allogeneic T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19. Patients with B-cell malignancies that had progressed after alloHSCT received a single infusion of CAR T cells. No chemotherapy or other therapies were administered. The T cells were obtained from each recipients alloHSCT donor. RESULTS Eight of 20 treated patients obtained remission, which included six complete remissions (CRs) and two partial remissions. The response rate was highest for acute lymphoblastic leukemia, with four of five patients obtaining minimal residual disease-negative CR. Responses also occurred in chronic lymphocytic leukemia and lymphoma. The longest ongoing CR was more than 30 months in a patient with chronic lymphocytic leukemia. New-onset acute graft-versus-host disease after CAR T-cell infusion developed in none of the patients. Toxicities included fever, tachycardia, and hypotension. Peak blood CAR T-cell levels were higher in patients who obtained remissions than in those who did not. Programmed cell death protein-1 expression was significantly elevated on CAR T cells after infusion. Presence of blood B cells before CAR T-cell infusion was associated with higher postinfusion CAR T-cell levels. CONCLUSION Allogeneic anti-CD19 CAR T cells can effectively treat B-cell malignancies that progress after alloHSCT. The findings point toward a future when antigen-specific T-cell therapies will play a central role in alloHSCT.
Blood | 2011
Jennifer Cuellar-Rodriguez; Juan Gea-Banacloche; Alexandra F. Freeman; Amy P. Hsu; Christa S. Zerbe; Katherine R. Calvo; Jennifer Wilder; Roger Kurlander; Kenneth N. Olivier; Steven M. Holland; Dennis D. Hickstein
We performed nonmyeloablative HSCT in 6 patients with a newly described genetic immunodeficiency syndrome caused by mutations in GATA2-a disease characterized by nontuberculous mycobacterial infection, monocytopenia, B- and NK-cell deficiency, and the propensity to transform to myelodysplastic syndrome/acute myelogenous leukemia. Two patients received peripheral blood stem cells (PBSCs) from matched-related donors, 2 received PBSCs from matched-unrelated donors, and 2 received stem cells from umbilical cord blood (UCB) donors. Recipients of matched-related and -unrelated donors received fludarabine and 200 cGy of total body irradiation (TBI); UCB recipients received cyclophosphamide in addition to fludarabine and TBI as conditioning. All patients received tacrolimus and sirolimus posttransplantation. Five patients were alive at a median follow-up of 17.4 months (range, 10-25). All patients achieved high levels of donor engraftment in the hematopoietic compartments that were deficient pretransplantation. Adverse events consisted of delayed engraftment in the recipient of a single UCB, GVHD in 4 patients, and immune-mediated pancytopenia and nephrotic syndrome in the recipient of a double UCB transplantation. Nonmyeloablative HSCT in GATA2 deficiency results in reconstitution of the severely deficient monocyte, B-cell, and NK-cell populations and reversal of the clinical phenotype. Registered at www.clinicaltrials.gov as NCT00923364.
Blood | 2011
Nicole J. Gormley; Jennifer Wilder; Hahn Khuu; Jeremy Pantin; Theresa Donohue; Roger Kurlander; Sawa Ito; Minoo Battiwalla; A. John Barrett; Sophie Grasmeder; Lisa Cook; Catalina Ramos; Patricia Prince; David F. Stroncek; Willy A. Flegel; Maria Berg; Robert N. Reger; Charles D. Bolan; Sharon Adams; Richard Childs
Biology of Blood and Marrow Transplantation | 2011
J.N. Kochenderfer; M.E. Dudley; Irina Maric; Steven A. Feldman; R. Salit; Nancy M. Hardy; P. Layton; Bazetta Blacklock-Schuver; Jennifer Wilder; L. Devillier; Ronald E. Gress; R.A. Morgan; S.A. Rosenberg; Michael R. Bishop
Blood | 2013
Mark E. Dudley; Robert O. Carpenter; Sadik H. Kassim; Jeremy J. Rose; William G. Telford; Frances T. Hakim; David Halverson; Daniel H. Fowler; Nancy M. Hardy; Anthony R Mato; Dennis D. Hickstein; Juan Gea-Banacloche; Steven Z. Pavletic; Claude Sportes; Irina Maric; Steven R. Feldman; Brenna Hansen; Jennifer Wilder; Bazetta Blacklock-Schuver; Bipulendu Jena; Michael R. Bishop; Steven A. Rosenberg; Ronald E. Gress
Blood | 2013
Xin Tian; Jennifer Wilder; Nicole Gormley; Hahn Khuu; David F. Stroncek; Susan F. Leitman; Roger Kurlander; Elena Cho; Lisa Cook; Catalina Ramos; Ladan Foruraghi; Charles D. Bolan; Richard Childs
Blood | 2015
Jennifer N. Brudno; Robert Somerville; Victoria Shi; Jeremy J. Rose; David Halverson; Daniel H. Fowler; Dennis D. Hickstein; Juan Gea-Banacloche; Steven Z. Pavletic; Andre Goy; Tangying L. Lu; Steven R. Feldman; Alex Iwamoto; Roger Kurlander; Irina Maric; Brenna Hansen; Jennifer Wilder; Bazetta Blacklock-Shuver; Frances T. Hakim; Steven A. Rosenberg; Ronald E. Gress; James N. Kochenderfer
Blood | 2015
Enkhtsetseg Purev; Georg Aue; Ritesh Kotecha; Jennifer Wilder; Hahn Khuu; David F. Stroncek; Roger Kurlander; Robert N. Reger; Willy A. Flegel; Sharon Adams; Lisa Cook; Catalina Ramos; Elena Cho; Richard Childs
Blood | 2010
Rachel B. Salit; Steven Z. Pavletic; Daniel H. Fowler; Jennifer Wilder; Kelly Bryant; Seth M. Steinberg; Frances T. Hakim; Michael R. Bishop